142 related articles for article (PubMed ID: 8428697)
1. The validity and significance of substages of advanced ovarian cancer.
Partridge EE; Gunter BC; Gelder MS; Alvarez RD; Soong SJ; Austin JM; Kilgore LC
Gynecol Oncol; 1993 Feb; 48(2):236-41. PubMed ID: 8428697
[TBL] [Abstract][Full Text] [Related]
2. Second-look laparotomy after modified posterior exenteration: patterns of persistence and recurrence in patients with stage III and stage IV ovarian cancer.
Spirtos NM; Eisenkop SM; Schlaerth JB; Ballon SC
Am J Obstet Gynecol; 2000 Jun; 182(6):1321-7. PubMed ID: 10871445
[TBL] [Abstract][Full Text] [Related]
3. The validity and significance of substage IIIC by node involvement in epithelial ovarian cancer: impact of nodal metastasis on patient survival.
Kanazawa K; Suzuki T; Tokashiki M
Gynecol Oncol; 1999 May; 73(2):237-41. PubMed ID: 10329040
[TBL] [Abstract][Full Text] [Related]
4. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients.
Obermair A; Sevelda P
Acta Obstet Gynecol Scand; 2001 May; 80(5):432-6. PubMed ID: 11328220
[TBL] [Abstract][Full Text] [Related]
5. Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?
Cliby WA; Aletti GD; Wilson TO; Podratz KC
Gynecol Oncol; 2006 Dec; 103(3):797-801. PubMed ID: 17052746
[TBL] [Abstract][Full Text] [Related]
6. Second-look laparotomy for ovarian cancer provides reliable prognostic information and improves survival.
Friedman RL; Eisenkop SM; Wang HJ
Gynecol Oncol; 1997 Oct; 67(1):88-94. PubMed ID: 9345362
[TBL] [Abstract][Full Text] [Related]
7. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients.
Colombo PE; Mourregot A; Fabbro M; Gutowski M; Saint-Aubert B; Quenet F; Gourgou S; Rouanet P
Eur J Surg Oncol; 2009 Feb; 35(2):135-43. PubMed ID: 18289825
[TBL] [Abstract][Full Text] [Related]
8. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
Eisenkop SM; Friedman RL; Wang HJ
Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
[TBL] [Abstract][Full Text] [Related]
9. Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study.
Williams L; Brunetto VL; Yordan E; DiSaia PJ; Creasman WT
Gynecol Oncol; 1997 Aug; 66(2):171-8. PubMed ID: 9264559
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; Gérard JP; Romestaing P; Carrie C
Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544
[TBL] [Abstract][Full Text] [Related]
11. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
12. [Significance of systematic retroperitoneal lymphadenectomy at second-look laparotomy for ovarian cancer].
Zhang ZY; Zang RY; Tang MQ; Chen J
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):69-71. PubMed ID: 12783690
[TBL] [Abstract][Full Text] [Related]
13. Times and sites of relapses after negative second look in advanced epithelial ovarian cancer.
Maggino T; Gadducci A; Romagnolo C; Fanucchi A; Fioretti P
Eur J Surg Oncol; 1994 Apr; 20(2):146-50. PubMed ID: 8181580
[TBL] [Abstract][Full Text] [Related]
14. Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer.
Bozkurt N; Yuce K; Basaran M; Kose F; Ayhan A
Obstet Gynecol; 2004 Jan; 103(1):82-5. PubMed ID: 14704249
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up.
Zivanovic O; Barakat RR; Sabbatini PJ; Brown CL; Konner JA; Aghajanian CA; Abu-Rustum NR; Levine DA
Cancer; 2008 Jun; 112(12):2690-7. PubMed ID: 18428210
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
Kuhn W; Schmalfeldt B; Reuning U; Pache L; Berger U; Ulm K; Harbeck N; Späthe K; Dettmar P; Höfler H; Jänicke F; Schmitt M; Graeff H
Br J Cancer; 1999 Apr; 79(11-12):1746-51. PubMed ID: 10206287
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
[TBL] [Abstract][Full Text] [Related]
18. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma.
Eitan R; Levine DA; Abu-Rustum N; Sonoda Y; Huh JN; Franklin CC; Stevens TA; Barakat RR; Chi DS
Cancer; 2005 Apr; 103(7):1397-401. PubMed ID: 15726548
[TBL] [Abstract][Full Text] [Related]
19. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
[TBL] [Abstract][Full Text] [Related]
20. Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer.
Aletti GD; Dowdy S; Podratz KC; Cliby WA
Am J Obstet Gynecol; 2006 Dec; 195(6):1862-8. PubMed ID: 17132488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
